Shots:

• The P-II PoC trial evaluates rilzabrutinib's (800mg & 1200mg, QD) safety, efficacy & tolerability vs PBO added to ICS/LABA background therapy for treating moderate-to-severe asthma patients not controlled on ICS plus LABA therapy
• The study depicted a 36% (high dose) & 25% (low dose) reduced risk in LOAC events at wk.12 plus improved asthma symptoms with a mean difference of -0.54/-0.59 LS in asthma control questionnaire, ACQ-5 at wk.2. This data will form the basis of P-III study to assess drug’s BID dosing
• Furthermore, the drug was well-tolerated without any occurrences of cytopenia, hemorrhagic events, atrial fibrillation & imbalance in liver function tests with 10.9% (high dose) & 9.4% (low dose) vs 0% & 3.1% TEAEs

Ref: Sanofi | Image: Sanofi

Related News:- Sanofi’s Rilzabrutinib Meets Primary Endpoint of the LUNA-3 (P-III) Study for the Treatment of Immune Thrombocytopenia (ITP)

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com